Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Prostaglandin B1 (PGB1) is a naturally occurring prostaglandin derivative formed by the dehydration and isomerization of Prostaglandin E1 (PGE1). In pharmacological research, PGB1 has been investigated as a potent ocular hypotensive agent. Studies in animal models, such as cats and rabbits, have demonstrated that B-type prostaglandins like PGB1 can significantly reduce intraocular pressure (IOP) with greater potency and a longer duration of action than primary prostaglandins like PGF2α. Notably, PGB1 appears to lower IOP without inducing significant miosis or anterior chamber inflammation, suggesting a potential therapeutic advantage for the treatment of glaucoma and ocular hypertension.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prostaglandin B1.